Ohba Akihiro, Kato Ken, Ito Yoshinori, Katada Chikatoshi, Ishiyama Hiromichi, Yamamoto Sachiko, Ura Takashi, Kodaira Takeshi, Kudo Shigehiro, Tamaki Yoshio
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Adv Radiat Oncol. 2016 Jul 15;1(4):230-236. doi: 10.1016/j.adro.2016.07.002. eCollection 2016 Oct-Dec.
The most effective treatments in elderly patients with esophageal cancer remain a subject of debate. This multicenter phase 2 study was designed to evaluate the efficacy and toxicity of chemoradiation therapy (CRT) with docetaxel (DTX) in elderly patients with stage II/III (non-T4) esophageal cancer.
Patients ≥70 years of age with clinical stage II/III esophageal cancer received DTX at a weekly dose of 10 mg/m during 6 consecutive weeks and concurrent radiation therapy (60 Gy in 30 fractions). The primary endpoint was the 2-year survival rate, and the required number of enrolled patients was 37.
Between July 2008 and January 2011, 16 patients were enrolled. The study was prematurely closed because of slow accrual. Characteristics of the patients were as follows: median age, 77 years (range, 73-81); performance status 0/1, 4/12; and clinical stage IIA/IIB/III, 3/4/9. Of the 16 patients, 14 (87.5%) completed the CRT. The 2-year survival rate was 62.5% (90% confidence interval [CI], 42.5-82.5). The median survival time was 27.7 months (95% CI, 23.3-32.2 months) and the median progression-free survival was 15.2 months (95% CI, 5.4-25.0 months). Seven patients achieved complete response, resulting in a complete response rate of 43.8% (95% CI, 19.8-70.1). Grade 3 or higher acute toxicities included esophagitis (31.3%), anorexia (12.5%), leukopenia (6.3%), neutropenia (6.3%), thrombocytopenia (6.3%), mucositis (6.3%), and infection (6.3%). Grade 3 or higher late toxicities included esophagitis (12.5%), pleural effusion (12.5%), pneumonitis (6.3%), and pericardial effusion (6.3%).
CRT with DTX might be a treatment option for elderly patients with stage II/III esophageal cancer, particularly for patients who are medically unfit for surgery or cisplatin-containing therapy. However, further improvements of this therapy are required to decrease the incidence of esophagitis.
老年食管癌患者最有效的治疗方法仍是一个有争议的话题。这项多中心2期研究旨在评估多西他赛(DTX)同步放化疗(CRT)在II/III期(非T4)老年食管癌患者中的疗效和毒性。
年龄≥70岁的临床II/III期食管癌患者连续6周每周接受10mg/m的DTX治疗,并同步放疗(30次分割,60Gy)。主要终点是2年生存率,预计入组患者数量为37例。
2008年7月至2011年1月,共入组16例患者。由于入组缓慢,研究提前结束。患者特征如下:中位年龄77岁(范围73 - 81岁);体能状态0/1,4/12;临床分期IIA/IIB/III,3/4/9。16例患者中,14例(87.5%)完成了CRT。2年生存率为62.5%(90%置信区间[CI],42.5 - 82.5)。中位生存时间为27.7个月(95%CI,23.3 - 32.2个月),中位无进展生存期为15.2个月(95%CI,5.4 - 25.0个月)。7例患者达到完全缓解,完全缓解率为43.8%(95%CI,19.8 - 70.1)。3级或更高等级的急性毒性包括食管炎(31.3%)、厌食(12.5%)、白细胞减少(6.3%)、中性粒细胞减少(6.3%)、血小板减少(6.3%)、黏膜炎(6.3%)和感染(6.3%)。3级或更高等级的晚期毒性包括食管炎(12.5%)、胸腔积液(12.5%)、肺炎(6.3%)和心包积液(6.3%)。
DTX同步放化疗可能是II/III期老年食管癌患者的一种治疗选择,特别是对于那些身体状况不适合手术或含顺铂治疗的患者。然而,需要进一步改进这种治疗方法以降低食管炎的发生率。